Background {#Sec1}
==========

Environmental enteric dysfunction was first described among adult Peace Corps volunteers returning from deployment to low and middle-income countries (LMIC) in the 1960s who presented with unexplained, persistent weight loss. Despite no specific, clearly identifiable infectious etiology, biopsies of intestinal tissue in these individuals demonstrated morphological changes suggestive of chronic enteric infection \[[@CR1], [@CR2]\]. The symptoms of these volunteers usually resolved within several months of returning to the USA \[[@CR3]\], further supporting the link between these histological changes and recurrent exposure to pathogens in areas of poor sanitation and hygiene. The hypothesized environmental etiology and histopathological evidence of enteropathy has led some investigators to call this condition 'environmental enteropathy' \[[@CR4], [@CR5]\]. However, evidence of decreased enteric absorptive capacity and barrier function associated with this enteropathy has led some investigators to shift from 'environmental enteropathy' to the term 'environmental enteric dysfunction' (EED) \[[@CR6], [@CR7]\]. In support of this hypothesis, abnormal biomarkers suggestive of EED have been found to be highly prevalent among children in multiple low-resource settings. These biomarkers have been associated with linear and ponderal growth deficits \[[@CR8]--[@CR11]\]. Given these findings, and the clear public health importance of malnutrition and growth failure, EED has become an important potential target for intervention.

Several environmental and nutritional factors can cause enteropathy in LMIC settings, including specific micronutrient deficiencies, diarrheal disease, and chronic infections such as HIV \[[@CR12]\]. The coarse histopathology of these conditions is similar, but the etiology of EED, and the mechanisms that link it to negative outcomes, are thought to be distinct. Unfortunately, it has been challenging to definitively establish the causes and consequences of EED -- in part because the condition lacks a universally accepted case definition, and there are no universally accepted diagnostic tests or set of diagnostic criteria for EED \[[@CR13]\]. As a result, accurately estimating the distribution, burden and underlying mechanisms driving EED is difficult.

The geographic distribution of EED suggests that the syndrome is most prevalent in areas of poor access to improved water and sanitation. In addition, biomarkers of EED have been strongly associated with storage of fecal matter near households and unimproved water sources in LMICs \[[@CR14]\]. These findings suggest that EED is the result of exposure to environmental contamination. Molecular detection of enteric pathogens has confirmed that children living in LMIC settings harbor concurrent and consecutive enteric pathogens for much of their early childhood \[[@CR15]--[@CR17]\]. The Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) study, a large multi-country birth cohort designed to evaluate causes of childhood stunting, reported that children with identified enteric pathogens exhibited increased enteric inflammation and decreased linear growth, even in the absence of diarrhea \[[@CR18]\]. Several specific pathogens, including *Campylobacter, Shigella, Yersinia* and *Giardia*, appear to have stronger associations with enteric inflammation and linear growth failure \[[@CR19]\]. Many of these pathogens primarily affect children over 6 months of age -- the age at which exclusive breastfeeding often ends, and the prevalence of stunting begins to increase rapidly \[[@CR20]\]. This timing may be a clue as to the age-specific window in which EED drives growth failure, and could represent an optimal period for EED focused interventions.

Mechanisms and consequences {#Sec2}
===========================

Five highly interdependent mechanisms may link EED to poor health outcomes: 1) increased intestinal permeability with translocation of bacteria or antigens, 2) chronic intestinal inflammation without translocation, 3) malabsorption, 4) hormonal disruption, and 5) microbiome disruption.

The healthy intestine serves as a physical barrier between the gut lumen and the systemic circulation. In EED, disruption of the gut architecture, with breakdown of tight junctions between cells, creates a permeable intestine that can allow bacteria or bacterial products to translocate into the systemic circulation \[[@CR18]\]. This may lead to subsequent immune activation and a systemic inflammatory state, with associated downstream health effects. For example, acute phase proteins induced by translocation have been shown to inhibit insulin-like growth factor 1 (IGF-1), and lead to growth hormone resistance \[[@CR21]\]. This may suppress linear growth \[[@CR22]\], affect cognitive development, and detrimentally affect immune responses to pathogen challenge \[[@CR23], [@CR24]\]. In addition, the indoleamine-2,3-dioxygenase 1 pathway serves as a marker of systemic inflammation, and has also been associated with reduced polio vaccine efficacy \[[@CR25]\]. However, it is important to note that chronic systemic inflammation can occur in the absence of translocation. To date, few studies have found direct evidence linking systemic inflammation to enteric translocation \[[@CR18], [@CR24]\].

Malabsorption also potentially links EED to negative outcomes. EED substantially damages intestinal structure, including causing shortened and blunted villi and crypt hyperplasia, which lead to a loss of absorptive intestinal surface area \[[@CR7], [@CR26]\]. Deficits in the absorption of essential nutrients arising from this loss of surface area could result in metabolic pathway derangement, or simply a mismatch between the availability and consumption of micronutrients and macronutrients. However, other models of poor absorptive capacity, such as that observed in children with inflammatory bowel disease, suggest that even when substantial sections of small intestine are resected, these children often maintain relatively normal gut function \[[@CR27]\]. Interestingly, while the MAL-ED study reported a strong association between the presence of systemic inflammation and linear growth, ponderal growth was less affected by inflammation. It may be that malabsorption is a more critical driver of weight loss and wasting than systemic inflammation \[[@CR18]\].

EED may also be associated with enteric microbiome dysbiosis. EED has been associated with changes to the microbiome, as loss of gut surface area and profound enteric inflammation alter the ecological niches that support certain bacterial taxa. The microbiome contributes to multiple homeostatic mechanisms, and undernourished children have been shown to have both a reduced diversity in the enteric microbiome, and a decrease in specific taxa associated with healthy childhood growth \[[@CR28], [@CR29]\]. Administration of these specific growth-promoting or growth-suppressing taxa have also been shown to reproduce or ameliorate growth failure in mice \[[@CR28]\]. A healthy microbiome protects against pathogen colonization and invasion, including with *Shigella* and other diarrheagenic pathogens, and may also protect against subclinical pathogen colonization and EED \[[@CR29]\]. The microbiome also aids the body in liberating calories from ingested food; EED-associated dysbiosis may exacerbate nutrient deficits \[[@CR29]\]. Finally, the microbiome is a key regulator of hormonal responses to feeding and fasting. These hormonal changes have been linked to EED, including reductions in IGF-1 and fibroblast growth factor 21 \[[@CR21], [@CR30]\].

Identification {#Sec3}
==============

EED is most clearly diagnosed by observing well-described alterations in the histology of the small intestine. As a result, upper gastrointestinal endoscopy with biopsy is the current gold standard for diagnosis. However, access to endoscopy is severely limited in most EED endemic settings, and -- even where available -- concerns about safety limit its utility for routine diagnosis. Although new technologies, such as capsule endoscopy with biopsy, may soon be available \[[@CR31], [@CR32]\], it is unlikely that endoscopy-based diagnostics will be implemented at scale.

Therefore, a variety of biomarkers targeting proposed pathways have been evaluated as EED diagnostics (Fig. [1](#Fig1){ref-type="fig"}). These biomarkers are less invasive than endoscopy, and are drawn from a variety of body compartments, including urine, stool and blood, but there are no widely accepted diagnostic criteria that utilize these tests. The dual-sugar permeability test has been the most widely implemented of these surrogate markers. This is based on the premise that a healthy intestine will absorb small sugars (mannitol or rhamnose), while keeping large sugars (lactulose) from entering the systemic circulation, thus delivering an active assessment of gut function \[[@CR33], [@CR34]\]. In EED, tight junctions between the intestinal cells are disrupted, allowing the larger sugars to pass into the body's circulation. As a result, both types of sugar are excreted by the kidney, and the ratio of the two sugars is indicative of the degree of permeability in the intestine. The lactulose:mannitol ratio (L:M) and lactulose:rhamnose ratio (L:R) have been shown to be associated with linear growth faltering \[[@CR8]\]. However, the test can take 2--5 hours, and requires considerable experience to implement. This procedure can also yield inconsistent results, perhaps owing to the lack of standardized procedures and reporting \[[@CR33]\]. Fig. 1Biomarkers of environmental enteric dysfunction (EED), microbiome dysfunction, systemic inflammation and growth hormone resistance. Adapted from McGrath (2017) \[[@CR17]\]. Abbreviations: AAT, α-1-antitrypsin; AGP, α-1 acid glycoprotein; CAL, calprotectin; CRP, C-reactive protein; EndoCAb, anti-endotoxin core antibody; FGF-21, fibroblast growth factor 21; Flic, flagellin; GH, Growth hormone; I-FABP, intestinal fatty acid binding protein; IgA, immunoglobulin A; IgG, immunoglobulin G; IGF-1, insulin-like growth factor 1; Kyn, kynurenine; K:T, kynurenine:tryptophan ratio; LPS, lipopolysaccharides; L:M, lactulose:mannitol; L:R, lactulose:rhamnose; MAZ, microbiota-for-age Z score; MPO, myeloperoxidase; NEO, neopterin; Reg1β, regenerating protein 1β; SIBO, small intestinal bacterial overgrowth; SIRT1, Sirtuin 1; Trp, tryptophan

Fecal and plasma biomarkers of inflammation are also available \[[@CR9], [@CR10], [@CR25], [@CR35], [@CR36]\]. However, no single biomarker or collection of biomarkers has been systematically validated across geographic settings and populations \[[@CR24], [@CR37]\]. Several ongoing studies are attempting to correlate these biomarkers with histology using selective endoscopy in specific populations \[[@CR38], [@CR39]\].

Prevention and management {#Sec4}
=========================

Effective interventions to prevent or treat EED in low-resource settings are limited. Given the apparent association between environmental exposures and EED, efforts to minimize environmental contamination through water, sanitation and hygiene (WASH) interventions have been a focus of several large interventional trials. Two recently completed, highly rigorous, cluster-randomized controlled trials estimated the efficacy of WASH interventions in reducing childhood diarrhea, limiting EED and improving childhood growth. A significant reduction in diarrhea incidence was observed among children receiving WASH interventions in Bangladesh, but this finding was not replicated in Kenya or Zimbabwe. Furthermore, WASH interventions were not associated with improved linear growth in any of these studies \[[@CR40]--[@CR42]\]. It is likely that community-wide improvements in water and sanitation infrastructure would lessen the burden of EED, but these studies suggest that individual or household-level WASH interventions may not provide sufficient protection from environmental contamination to prevent or ameliorate EED.

Treatment of documented EED may be a more feasible approach given the ubiquitous environmental contamination in many LMIC settings. Several recently completed or ongoing studies are evaluating approaches to reducing the impact of EED in LMIC settings. We identified 16 ongoing or completed interventional studies (Table [1](#Tab1){ref-type="table"}) of interventions for EED, which we group into three strategies: anti-inflammatory drugs, antimicrobial interventions and dietary supplements. Table 1Interventional studies testing management strategies for EED, or using interventions to better understand EEDStudy titleStudy populationTarget sample sizeIntervention arm(s)Control arm(s)Primary outcome(s)**Complete** Lactoferrin and lysozyme supplementation for environmental enteric dysfunctionChildren 12--25 months old, Malawi235Lactoferrin and lysozyme, 16 weeksPlaceboL:M at 8 and 16 weeks The impact of legumes vs corn-soy flour on environmental enteric dysfunction in rural Malawian children 1--3 year oldsChildren 12--35 months old, Malawi337Cowpeas complementary food, 12 monthsCommon bean complementary food, 12 monthsCorn-soy flourL:M at 3, 6, and 12 months The impact of legumes vs corn-soy flour on environmental enteric dysfunction in rural Malawian children 6--11 monthsChildren 6--11 months old, Malawi312Cowpeas complementary food, 6 monthsCommon bean complementary food, 6 monthsCorn-soy flourL:M at 3 and 6 months Intervention and mechanisms of alanyl-glutamine for inflammation, nutrition, and enteropathy (IMAGINE)Children 2 months to 5 years old, ≤ − 1 for: HAZ WAZ, or WHZ, Brazil112Alanyl-glutamine, 10 daysGlycine for 10 daysL:M on D 1, 10--13, 30--37 Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunctionChildren 12--60 months old with mid upper arm circumference \< 11.5 cm or bilateral pedal edema, Kenya44Mesalazine, 28 daysPlaceboSafety and acceptability at 28 days**Ongoing** Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children (Toto Bora)Children 1--59 months old discharged from hospital, Kenya1400Azithromycin, 5 daysPlaceboDeath or readmission with 6 months Pilot study of PTM202 for the treatment of environmental enteric dysfunction (EED)Children 6--9 months old WAZ −1 to − 3, Bangladesh200PTM202, 30 daysMicronutrient sprinklesEED biomarker composite score (REG1B, MPO, L:M, sCD14, CRP) at 4 months Clinical effectiveness trial of PTM1001 to reduce stunting and ameliorate environmental enteric dysfunction in Malawian infantsHealthy children 10 months old, Malawi250Egg powder + bovine colostrum + multiple micronutrient sprinkle powder, 12 weeksCorn-soya blend + multiple micronutrient sprinkle powderLinear growth at 12 weeks Protein Plus: improving infant growth through diet and enteric health (JiVitA-6)Children 3--6 months old born to women enrolled in ongoing community trial, Bangladesh3180AzithromycinAzithromycin, proteinAzithromycin, isocaloric supplementAzithromycin, daily egg provided to infants 6--12 months 3 daysPlaceboPlacebo, protein supplementPlacebo, isocaloric supplement,Placebo, egg provided daily to infants 6--12 months oldHAZ at 12 months Effects of EED on Zinc absorption and retention in children from a standard dose (ZEED1)Children with and without EED (defined by L:M), Bangladesh40Zinc sulfate supplement, 0.5 mg of 13C10-retinyl-acetate,1 day--Zinc absorptionEndogenous fecal zincVitamin A absorption Effects of EED on Zinc absorption and retention in children from a MNP (ZEED2)Children 18--24 months old with LAZ−1.5 to −3.0 and hemoglobin ≥8, Bangladesh80Micronutrients + 15 mg zincMicronutrients + 10 mg zincMicronutrient + 5 mg zinc1 dayMicronutrient without zincTotal daily absorbed zinc Early life interventions for childhood growth and development in Tanzania (ELICIT)Children ≤14 days old, Tanzania1188Nicotinamide, azithromycin, nitazoxanidePlacebo, azithromycin, nitazoxanideNicotinamide, placebo, placeboAzithromycin, placebo, Nitazoxanide, placeboHAZ at 18 months Safety, acceptability, and feasibility of Enterade® (SAFE)Children 12--24 months old, HAZ − 3 to − 1, Kenya66Enterade, 14 daysPlaceboFrequency of severe adverse eventsVolume of daily consumption Therapeutic approaches to malnutrition enteropathy (TAME)Children 6--59 months old, hospitalized with severe acute malnutrition and clinically stable, Zambia235ColostrumGInNACTeduglutideBudenoside14 daysStandard of care WHO guidelines of severe acute malnutritionEED composite score at 18 days Study of environmental enteropathy and malnutritionChildren 0--6 months old, WHZ \< −2, PakistanChildren 0--6 months old, WHZ \> 0, PakistanHealthy children \< 3 years old, USAChildren \< 6 years old, newly diagnosed celiac disease, USAChildren \< 10 years old with newly diagnosed Crohn's disease, USA500Ready-to-use supplementary foods (AchaMum), 60--90 daysEducational program focused on breastfeeding and complementary feedingNo intervention: US children with celiac disease, Crohn's disease, and healthy age-matched US childrenNutritional status at 3--6 months and 9 monthsAssociation biomarkers with EED at 3--6 monthsAssociation of biomarkers with EED at 9 monthsAssociation biomarkers at time of endoscopy and biopsyUpper gastrointestinal tissue biopsy and multiomic validation of EED biomarkers Environmental enteropathy in Zambia: biomarkers defined by pathogenesisChildren \< 18 months old, HAZ \< − 2, Zambia400HEPS (corn-soya blend) + daily egg + micronutrient sprinkles--UGI endoscopy with validation of EED biomarkers*Abbreviations: EED* Environmental enteric dysfunction, *HAZ* Height-for-age z-score, *L:M* Lactulose-to-mannitol ratio, *WAZ* Weight-for-age z-score, *WHZ* Weight-for-height z-score

Therapeutics developed for inflammatory bowel disease may have a role in treating EED, as these conditions share features of enteric inflammation, loss of intestinal architecture and systemic inflammation. However, many of these medications have adverse side effect profiles, and may not be acceptable for use in young children in these settings. The safety of mesalazine use has been evaluated in malnourished children, and no detectable increase in adverse events was reported \[[@CR43]\]. In addition, a pilot trial of budesonide is ongoing in Zambia and Zimbabwe.

Given the hypothesized role of enteric infection in the pathogenesis of EED, several studies are attempting selective gut decontamination with antimicrobials \[[@CR44], [@CR45]\]. Antibiotics may promote linear growth \[[@CR46]\], and recent trials of biannual azithromycin mass drug administration (MDA) have demonstrated a reductions in all cause childhood mortality \[[@CR47]\]. Antibiotics may also provide a pathogen-free window for the enteric system to recover following insult. Although there are clearly concerns related to the emergence of antimicrobial resistance, antibiotics are already widely utilized in these settings. For example, children under the age of two included in the MAL-ED study received an average of five courses of antibiotics per year \[[@CR48]\]. In addition, determining whether antibiotics play an important role in the management of EED would permit more clear guidelines for antibiotic use, which has been shown to result in decreased misuse of antibiotics overall \[[@CR49]\]. There is also considerable interest in the use of probiotics or prebiotics for the treatment of EED, but to date only a single study has evaluated the administration of a probiotic (*Lactobacillus* GG) and it found no effect on measures of EED \[[@CR50]\].

We identified 10 trials evaluating dietary supplements for EED. These can be divided into protein supplementation, micronutrient supplementation, probiotics, and naturally occurring novel supplements. Five studies combine dietary supplementation with additional protein or other complementary foods, both of which have been shown to increase childhood growth \[[@CR51]--[@CR54]\]. Extensive evidence also exists regarding the role of many micronutrients in promoting childhood growth, largely demonstrating no association or clinically insignificant effects when supplements are provided \[[@CR55], [@CR56]\]. The prospect of treating or preventing EED with micronutrients that modulate the immune response, for example with the use of nicotinamide, is the subject of current evaluation \[[@CR45]\].

Four studies of novel dietary supplements were identified, including breast milk derivatives and alanyl-glutamine. Identifying components of breast milk that protect children from diarrhea in the first six-months of life may offer the opportunity to supplement beyond this period and provide extended protection to older children. A recently published study of bovine and recombinant human lactoferrin and lysozyme reported no significant effect on lactulose excretion \[[@CR53]\]. However, the intervention did reduce the incidence of malnutrition and hospitalization in the included children. In addition, two studies are currently piloting the use of bovine colostrum derivates \[[@CR57], [@CR58]\], one in combination with N-acetyl glucosamine, an amino acid thought to reduce enteric inflammation \[[@CR59]\].

In addition to identifying effective interventions, considering the optimal delivery strategy for these interventions are also needed. Given the highly prevalent nature of EED in many settings, empiric treatment of entire populations through MDA may be a viable delivery mechanism. MDA is a highly equitable delivery platform \[[@CR60]\], which may help to ensure that the highest risk children are effectively captured for intervention. However, MDA requires that interventions are inexpensive and safe, which limits its ability to support many of the therapeutics currently being evaluated. Screen-and-treat approaches are an alternative to MDA, but this approach would be complicated by the lack of a universally accepted case definition for EED, or an easily administered diagnostic \[[@CR13]\]. Screen-and-treat policies are also relatively more expensive. Interventions could also be administered to a targeted group of high-risk individuals, such as severely malnourished children or children presenting to medical facilities with an acute illness. Given that mortality is concentrated in these populations, this strategy may reach the greatest number of children with capacity to benefit, while limiting the cost and drug exposure of a less targeted approach \[[@CR61]\]. However, achieving high coverage in selected populations can be challenging. Community-Based Management of Acute Malnutrition programs are highly cost-effective \[[@CR61]--[@CR63]\], but only reach 17% of acutely malnourished children \[[@CR64]\], and only 44% of children with diarrhea currently receive oral rehydration solution \[[@CR65]\]. These data suggest that the malnutrition management and medical care platforms in LMIC settings would also benefit from investment and scale-up if they are to be an effective EED treatment platform.

Conclusion {#Sec5}
==========

Understanding and addressing the etiology of childhood wasting and stunting, and the consequences of these syndromes, remains a global public health priority. Significant strides have been made in linking environmental exposure to enteric pathogens and toxins with EED, and in understanding the multifactorial mechanisms underlying this complex condition. Further insights may come from several ongoing and upcoming interventional studies, which propose several novel management strategies. However, the potential of these interventions to reduce the global burden of morbidity associated with EED will be limited by the strength of the delivery platforms they target. It is vital that novel intervention development is accompanied by investment in healthcare platforms that can be leveraged to deliver effective managements.
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